Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19285856 | 0.68 | — | — | |
| SCHEMBL9193124 | 0.68 | — | — | |
| SCHEMBL12595244 | 0.68 | — | — | |
| SCHEMBL2254520 | 0.68 | — | — | |
| SCHEMBL2286486 | 0.65 | — | — | |
| SCHEMBL3626543 | 0.65 | — | — | |
| SCHEMBL31618869 | 0.65 | — | — | |
| SCHEMBL13841507 | 0.64 | PLAU (0.34) | PLAU | |
| SCHEMBL18346643 | 0.64 | CYP1A2 (0.34) | PLAU | |
| SCHEMBL8171161 | 0.64 | PLAU (0.41) | PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183277-B2 | Inhibitors of HCV replication of formula (I)** Image-1whereinW is a heterocycle of formula** Image-2and the remaining variables are as defined in the specification. | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2012-05-22 | — | — | US | disclosed |
| US-20110237621-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2011-09-29 | — | — | US | disclosed |
| US-20100120855-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. | 2010-05-13 | — | — | US | disclosed |
| US-20090247512-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2009-10-01 | — | — | US | disclosed |
| US-20080262058-A1 | Macrocylic Inhibitors of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262058-A1 | Macrocylic Inhibitors of Hepatitis C Virus | HAVCR2, HCCS, EIF2AK2 | PLAU 2541/4885 |
| US-20100120855-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | NR4A1, NR4A3, NR4A2 | PLAU 4579/4885 |
| US-20110237621-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | NR4A1, NR4A3, NR4A2 | PLAU 4753/4885 |
| US-20090247512-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | CYP2A7, CYP2B6, HCCS | PLAU 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.